体育博彩

New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma Accepted by NMPA
2021-08-05
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma Accepted by NMPA
PD-1/CTLA-4 Bi-specific Antibody in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Solid Tumors
2021-08-04
PD-1/CTLA-4 Bi-specific Antibody in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Solid Tumors
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Initiated Phase III Clinical Trial for First-Line Treatment of Advanced Gastric Cancer, National Researchers’ Conference Successfully Held
2021-08-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Initiated Phase III Clinical Trial for First-Line Treatment of Advanced Gastric Cancer, National Researchers’ Conference Successfully Held
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
2021-07-13
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
Michael Xi: Anti-PD-1 bi-specific antibodies mark the immuno-oncology era 2.0
2021-07-09
Michael Xi: Anti-PD-1 bi-specific antibodies mark the immuno-oncology era 2.0
Completed Patient Enrollment of the First Cohort with PD-1/CTLA-4 Bispecific Antibody (AK104) in Combination with CD47 Monoclonal Antibody (AK117) for Treatment of Solid Tumors
2021-07-06
Completed Patient Enrollment of the First Cohort with PD-1/CTLA-4 Bispecific Antibody (AK104) in Combination with CD47 Monoclonal Antibody (AK117) for Treatment of Solid Tumors
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Cancer
2021-07-05
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Cancer
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for First-Line Treatment of Squamous Non-Small-Cell Lung Cancer Accepted by NMPA
2021-07-02
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for First-Line Treatment of Squamous Non-Small-Cell Lung Cancer Accepted by NMPA
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
2021-06-30
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals
2021-06-21
Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals
Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award
2021-06-18
Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award
Out-Licensed by Akeso to MSD for US$200 Million, Monoclonal Antibody CTLA-4 Entered Phase III Clinical Trial
2021-06-16
Out-Licensed by Akeso to MSD for US$200 Million, Monoclonal Antibody CTLA-4 Entered Phase III Clinical Trial
威尼斯人娱乐城 欧洲杯体育下注 熊猫体育 皇冠体育官网 买足球外围平台推荐